Literature DB >> 30046446

The role of hydroxychloroquine in catastrophic antiphospholipid syndrome case: Series of two case reports and review of literature.

Zakaria Hindi1, Mosa Hussein2, Abdallah Gad1, Abdallah A Khaled3, Talal Zahoor1.   

Abstract

Catastrophic antiphospholipid syndrome is a rare disorder that remains under-recognized causing a high mortality rate even with treatment. Factors such as infections and systemic lupus erythematosus flare play as an inciting event in the thrombotic crisis which underlies catastrophic antiphospholipid syndrome. The use of plasmapheresis has improved the outcome of such cases with a reduction in mortality rate from over 50% to less than 30%, according to some studies. However, the definitive treatment of this disabling and fatal condition remains an area warranting research. Case 1. A case of 32-year-old female with a background of epilepsy and recurrent abortions who presented with difficulty in breathing, dry cough, and bilateral lower limb swelling. The patient initially received treatment with cyclophosphamide and systemic corticosteroids after being diagnosed with systemic lupus erythematosus. She also underwent plasmapheresis for suspected pulmonary hemorrhage as her condition deteriorated rapidly requiring intensive care. The diagnosis was revised as catastrophic antiphospholipid syndrome given the typical multi-organ involvement, namely, cerebritis, Libman-Sacks endocarditis, and nephritis apart from the pulmonary involvement. Eventually, hydroxychloroquine was added to the regimen which led to a remarkable improvement in her condition after a few days. Case 2. A case of 28-year-old female with history of recurrent abortions presented with abdominal pain and was admitted as a case of pancreatitis. The patient received intravenous fluids and analgesics with no significant improvement. Later, she developed multi-organ failure requiring critical care. Given her history and clinical presentation along with the multi-organ involvement in an acute setting, she underwent extensive workup that favored catastrophic antiphospholipid syndrome and she was started on Aspirin initially, and then, hydroxychloroquine was administered. Few days after initiation, her condition improved markedly and with complete resolution of her abdominal symptoms. Hydroxychloroquine's antithrombotic effect in synergy with other therapies has been observed in our cases. Yet, its role in the early course of catastrophic antiphospholipid syndrome merits further investigation.

Entities:  

Keywords:  Antiphospholipid antibodies; antiphospholipid syndrome; hydroxychloroquine

Year:  2018        PMID: 30046446      PMCID: PMC6055236          DOI: 10.1177/2050313X18782808

Source DB:  PubMed          Journal:  SAGE Open Med Case Rep        ISSN: 2050-313X


  12 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

2.  Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.

Authors:  Ricardo G Espinola; Silvia S Pierangeli; Azzudin E Gharavi; E Nigel Harris; Azzudin E Ghara
Journal:  Thromb Haemost       Date:  2002-03       Impact factor: 5.249

3.  Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.

Authors:  Bas de Laat; Xiao-Xuan Wu; Menno van Lummel; Ronald H W M Derksen; Philip G de Groot; Jacob H Rand
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

Review 4.  Catastrophic antiphospholipid syndrome.

Authors:  Setu K Vora; Ronald A Asherson; Doruk Erkan
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

5.  Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients.

Authors:  Silvia Bucciarelli; Gerard Espinosa; Ricard Cervera; Doruk Erkan; José A Gómez-Puerta; Manuel Ramos-Casals; Josep Font; Ronald A Asherson
Journal:  Arthritis Rheum       Date:  2006-08

Review 6.  Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome.

Authors:  J H Rand; X X Wu; A S Quinn; D J Taatjes
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

7.  Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Authors:  Nataliya Mar; Rebecca Kosowicz; Karen Hook
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 8.  Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.

Authors:  R A Asherson; R Cervera; P G de Groot; D Erkan; M C Boffa; J C Piette; M A Khamashta; Y Shoenfeld
Journal:  Lupus       Date:  2003       Impact factor: 2.911

9.  Catastrophic antiphospholipid syndrome: task force report summary.

Authors:  R Cervera; I Rodríguez-Pintó
Journal:  Lupus       Date:  2014-10       Impact factor: 2.911

10.  A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

Authors:  D Erkan; Y Yazici; M G Peterson; L Sammaritano; M D Lockshin
Journal:  Rheumatology (Oxford)       Date:  2002-08       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.